Boston, MA, United States

Northeastern University

www.northeastern.edu
Boston, MA, United States

Northeastern University is a private nonprofit research university located in Boston, Massachusetts. The university features a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools, as well as advanced degrees at graduate campuses in Charlotte, North Carolina, and Seattle, Washington.Northeastern's main campus is located in the Fenway, Roxbury, South End, and Back Bay neighborhoods. The university has roughly 16,000 undergraduates and almost 8,000 graduate students. Northeastern is categorized as a RU/H Research University by the Carnegie Classification of Institutions of Higher Education. In 2011, Northeastern opened the George J. Kostas Research Institute for Homeland Security.Northeastern features a cooperative education program that integrates classroom study with professional experience on seven continents. In 2012-2013, 7,968 students participated in the co-op program.The Northeastern University Huskies compete in the NCAA Division I as members of Colonial Athletic Association in 18 varsity sports offered by the CAA. The men's and women's hockey teams compete in Hockey East, while the men's and women's rowing teams compete in the Eastern Association of Rowing Colleges and Eastern Association of Women's Rowing Colleges , respectively. In 2013, men's basketball won its first CAA regular season championship, men's soccer won the CAA title for the first time, and women's ice hockey won a record 16th Beanpot championship. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Northeastern University, Dana-Farber Cancer Institute, Brigham and Women's Hospital | Date: 2017-05-31

A method of detecting migration of tumor cells is provided by implanting in a region of tumor cells one or more implants having a matrix material of a biocompatible and biodegradable polymer, and a plurality of nanoparticles dispersed within the matrix material and functionalized to bind tumor cells. Nanoparticles bound to the tumor cells that have migrated out of the region can be detected by various imaging modalities. The implant can be in the shape of a brachytherapy spacer or radiotherapy fiducial maker or can be a coating on a brachytherapy spacer or fiducial marker. A method of treating cancer is provided by implanting one or more brachytherapy spacers or fiducial markers including the matrix material and an anti-cancer therapeutic agent dispersed within the matrix material.


Disclosed herein are systems and methods to detect and manage information leaks resulting from network flows generated responsive to user interaction with a computing device(105). For example, an information leak control system (110) may be configured to generate an information leak model using at least one labeled network flow comprising at least one labeled information leak, detect an information leak of a device network flow of at least one device based on the information leak model, receive user feedback associated with the information leak, and update the model based on the user feedback. In addition, the information leak control system may be configured to present information leaks to users via a graphical user interface (130) configured to allow users to provide the user feedback. In some examples, the information leak control system may be configured to modify the device network flow based on the information leak and/or the user feedback.


Nanoparticulate carrier formulations are useful to solubilize, deliver, and target hydrophobic drugs for treating diseases including cancer and bacterial infections. The formulations contain amphiphilic peptides having a hydrophobic portion and a positively charged hydrophilic portion. The peptides self-associate at nonacidic pH to form micelles with a spherical nanoparticle morphology. The hydrophobic core of the nanoparticles encapsulates hydrophobic drugs, including antitumor agents, increasing their solubility in water and allowing them to be targeted, for example, to cancer cells. The positively charged surface of the nanoparticles, together with an optional targeting moiety such as an RGD peptide, allows the nanoparticles to bind selectively to mammalian cells and bacterial cells, including cancer cells that overexpress integrin receptors. The pH-dependence of the nanoparticle association/dissociation can be employed to conveniently load the nanoparticles with hydrophobic drug using a controlled pH shift, and unload them in acidic intracellular compartments. The ability of the carrier formulations to solubilize and target hydrophobic drugs gives rise to strategies for the selective inhibition or killing of cancer cells, such as the killing of osteosarcoma cells using the drug curcumin. The amphiphilic peptides and nanoparticles derived therefrom also give rise to additional compositions and methods that have useful bacteriocidal features as well as the ability to promote cell adhesion in cell scaffolds and coatings for medical implants.


Patent
Northeastern University | Date: 2017-04-12

A method and apparatus for producing a composite part are provided to enable composite parts to be assembled with precise control over the orientation and spatial distribution of reinforcing or other particles within a matrix material. The method and apparatus use magnetic fields applied during various additive manufacturing processes to achieve complex particles orientations within each layer of the part. The composite parts can achieve enhanced properties, including mechanical, thermal, electrical and optical properties.


Patent
Tilly, Woods and Northeastern University | Date: 2017-02-01

The present technology provides for methods for generation and isolation of granulosa cells and/or granulosa cell precursors from multi-potent cells, wherein the granulosa cells and/or granulosa cell precursors are useful in methods for growth and maturation of follicles or follicle-like structures. Additionally, the present technology also provides for methods of increasing steroidal hormones in a subject in need thereof.


Patent
Northeastern University | Date: 2017-05-03

A microfluidic device provides high throughput generation and analysis of defined three-dimensional cell spheroids with controlled geometry, size, and cell composition. The cell spheroids of the invention mimic tumor microenvironments, including pathophysiological gradients, cell composition, and heterogeneity of the tumor mass mimicking the resistance to drug penetration providing more realistic drug response. The device is used to test the effects of antitumor agents.


Patent
Northeastern University | Date: 2017-01-06

The invention relates to bioactive surface coatings deposited on selected substrates. Surface nanostructured film coatings deposited on most metal or nonmetal substrates to provide surfaces can be engineered to promote enhanced tissue/cell adhesion. Attached cells, including osteoblasts, fibroblasts and endothelial cells, retain viability and will readily differentiate and proliferate under appropriate conditions. Fibroblasts and endothelial cells exhibit good attachment and growth on most coated substrates, except on nano surfaced structured silicone.


Torchilin V.,Northeastern University
Advanced Drug Delivery Reviews | Year: 2011

Enhanced permeability and retention (EPR) effect is the physiology-based principal mechanism of tumor accumulation of large molecules and small particles. This specific issue of Advanced Drug Delivery Reviews is summing up multiple data on the EPR effect-based drug design and clinical outcome. In this commentary, the role of the EPR effect in the intratumoral delivery of protein and peptide drugs, macromolecular drugs and drug-loaded long-circulating pharmaceutical nanocarriers is briefly discussed together with some additional opportunities for drug delivery arising from the initial EPR effect-mediated accumulation of drug-containing macromolecular systems in tumors. © 2010 Elsevier B.V.


Torchilin V.P.,Northeastern University
Advanced Drug Delivery Reviews | Year: 2012

Currently used pharmaceutical nanocarriers, such as liposomes, micelles, nanoemulsions, polymeric nanoparticles and many others demonstrate a broad variety of useful properties, such as longevity in the blood allowing for their accumulation in pathological areas with compromised vasculature; specific targeting to certain disease sites due to various targeting ligands attached to the surface of the nanocarriers; enhanced intracellular penetration with the help of surface-attahced cell-penetrating molecules; contrast properties due to the carrier loading with various contrast materials allowing for direct carrier visualization in vivo; stimuli-sensitivity allowing for drug release from the carriers under certain physiological conditions, and others. Some of those pharmaceutical carriers have already made their way into clinic, while others are still under preclinical development. What could be seen much more rare, however, are the pharmaceutical nanocarriers combining several from the listed abilities. Long-circulating immunoliposomes capable of prolonged residence in the blood and specific target recognition represent one of few examples of this kind. At the same time, the enginnering of multifunctional pharmaceutical nanocarriers combinig several useful preoperties in one particle can significantly enhance the efficacy of many therapeutic and diagnostic protocols. This paper considers current status and possible future directions in the emerging area of multifunctional nanocarriers with primary attention on the combination of such properties as longevity, targetability, intracellular penetration and contrast loading. © 2012 Elsevier B.V.


Lewis K.,Northeastern University
Nature Reviews Drug Discovery | Year: 2013

The spread of resistant bacteria, leading to untreatable infections, is a major public health threat but the pace of antibiotic discovery to combat these pathogens has slowed down. Most antibiotics were originally isolated by screening soil-derived actinomycetes during the golden era of antibiotic discovery in the 1940s to 1960s. However, diminishing returns from this discovery platform led to its collapse, and efforts to create a new platform based on target-focused screening of large libraries of synthetic compounds failed, in part owing to the lack of penetration of such compounds through the bacterial envelope. This article considers strategies to re-establish viable platforms for antibiotic discovery. These include investigating untapped natural product sources such as uncultured bacteria, establishing rules of compound penetration to enable the development of synthetic antibiotics, developing species-specific antibiotics and identifying prodrugs that have the potential to eradicate dormant persisters, which are often responsible for hard-to-treat infections. © 2013 Macmillan Publishers Limited. All rights reserved.

Loading Northeastern University collaborators
Loading Northeastern University collaborators